Core Viewpoint - The SynBioCon 2025 conference will focus on the integration of AI with biomanufacturing, green chemicals and new materials, future food, and future agriculture, aiming to explore the development trends of the biomanufacturing industry during the 14th Five-Year Plan period [1]. Organizers and Support Units - The conference is organized by Ningbo Detaizhong Research Information Technology Co., Ltd. and supported by various institutions including Peking University Ningbo Institute of Ocean Medicine and the China Society of Biotechnology [2]. Expert Guests - Notable experts include Zhang Xian'en, Dean of the School of Synthetic Biology at Shenzhen University, and other prominent figures from various universities and research institutes who will share insights on biomanufacturing innovations [4][5][6][7]. Conference Agenda - The event will feature a series of forums and discussions, including a high-level roundtable on biomanufacturing, thematic forums on green chemicals and new materials, AI in biomanufacturing, and future food and agriculture [36][37]. Key Topics of Discussion - Topics will cover the construction of efficient cell factories for aromatic compounds, biomanufacturing of polyamide materials, and advancements in enzyme engineering for low-carbon biomanufacturing [8][11][27]. Networking and Collaboration - The conference aims to facilitate technology transfer, product scaling, and talent acquisition within the biomanufacturing sector, promoting collaboration among industry leaders, researchers, and government entities [1]. Event Details - The SynBioCon 2025 will take place from August 20 to 22 in Ningbo, Zhejiang, featuring registration, networking opportunities, and a showcase of technological achievements in the biomanufacturing field [1][36].

全球政策进展 | 青岛市 【SynBioCon】 获 悉，近日青岛市 发布 《青岛市合成生物创新发展行动方案（ 2025-2027 年）》 近日公布，部分内容如下： 一、总体要求 针对合成生物交叉范围广、技术开发壁垒高、应用领域广泛、产业发展潜力大等特点，以创新为动力，以企业为主体，以场景为牵引，以标志性产品为 抓手，推动合成生物技术广泛赋能医疗健康、环境保护、农业生产、能源化工等重要产业高质量发展，加快形成新质生产力，全面提升青岛合成生物科 技创新策源能力和产业发展能级。 到 2027 年，力争突破关键技术不少于 30 项，形成国际先进水平创新成果不少于 5 项 ，新增生物制造领域各级创 新平台不少于 5 个，打造标志性产业化项目不少于 10 项 ，培育一批高成长企业，瞪羚、专精特新、科技领军企业总计突破 30 家 ，新增具有国际影 响力的顶尖科学家团队不少于 2 个，打造特色鲜明、优势突出的产业载体或专业园区，建好用好青岛合成生物技术创新联盟和合成生物产业基金，营造 创新活跃、转化顺畅、主体繁荣、要素完备的产业生态，构建国内独具优势、彰显青岛特色的合成生物制造产业体系。 二、重点任务 （一）实施底层技术迭 ...

Fiscal 2025 2Q Financial Results M A Y 2 0 2 5 Agenda Welcome Angela Bitting SVP, Corporate Affairs 2 | TWIST BIOSCIENCE | PROPRIETARY Quarterly Highlights Emily Leproust Chief Executive Officer Business Highlights Patrick Finn President and Chief Operating Officer Financial and Operational Performance Adam Laponis Chief Financial Officer Milestones Emily Leproust Chief Executive Officer Q&A Session Legal Disclaimers This presentation contains forward-looking statements. All statements other than statements ...

Financial Data and Key Metrics Changes - For the second quarter of fiscal 2025, the company reported record revenue of $92.8 million, an increase of 23% year over year and 4.6% sequentially [13][24] - Gross margin for the quarter was 49.6%, up from 41% in the same quarter of fiscal 2024, reflecting improved operational efficiency [13][29] - Adjusted EBITDA loss was approximately $14.8 million, an improvement of about $11.9 million compared to the second quarter of fiscal 2024 [30] Business Line Data and Key Metrics Changes - Revenue from Synbio increased to $36 million, a growth of 21% year over year [13][24] - NGS revenue grew to approximately $51.1 million, an increase of 25% year over year [16][25] - Biopharma services revenue was $5.7 million, reflecting a growth of 21% year over year [16][25] Market Data and Key Metrics Changes - Healthcare revenue rose to $52.8 million, up 29% year over year [26] - Industrial chemical revenue increased to $22.8 million, a 12% rise from the previous year [26] - Academic revenue was $16.5 million, up 20% year over year [27] Company Strategy and Development Direction - The company has spun out DNA Data Storage as an independent entity, Atlas Data Storage, to focus on commercialization and drive success [9][11] - The strategy emphasizes operational agility and customer engagement to maintain competitive positioning [18][19] - The company aims to achieve adjusted EBITDA breakeven by the end of fiscal 2026, with a focus on innovation and market share growth [34][35] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong order bookings exceeding $100 million in the last two quarters [38] - The company is prepared to navigate market volatility and leverage it as an opportunity for growth [36][38] - Management acknowledged challenges in the academic sector but remains confident in the value proposition of their products [72][74] Other Important Information - The company ended the quarter with cash, cash equivalents, and short-term investments of approximately $257.1 million [31] - The company expects gross margin improvements to exceed 50% in the latter half of the fiscal year [34] Q&A Session Summary Question: Impact of tariffs on guidance and demand from competitors - Management indicated that they have accounted for potential tariff impacts in their guidance and noted strong share gains despite macro challenges [40][42] Question: Effect of promotions on academic market growth - Management confirmed that the 20% growth in the academic market was partly due to promotional activities, which they plan to continue until the end of the fiscal year [47][50] Question: Guidance for NGS revenue from top customers - Management expects growth from both existing and new customers, with top customers growing at a rate similar to the overall NGS business [53][54] Question: Reinvestment of savings from the spin-off into R&D - Management confirmed that savings from the spin-off will be partially reinvested into higher priority R&D initiatives [56][61] Question: Academic market's importance and growth assumptions - Management highlighted a significant opportunity in the academic market, with expectations for continued growth despite budget constraints [83][84]

Twist Bioscience (TWST) Q2 2025 Earnings Call May 05, 2025 08:00 AM ET Speaker0 day. Thank you for standing by. Welcome to Twist Bioscience's Second Quarter Financial Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please note that today's conference is being recorded. I would now like to turn the call over to Angela Bidding, SVP of Corporate Affairs. Please go ahead. Speaker1 Thank you, operato ...

作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金各 方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投资家， 在产业发展中发挥着重要作用。 融行业智慧、共襄盛举 聚产业力量、擘画未来 第三届SynBio Suzhou中国合成生物学"科学家+企业家+投资家"大会 将于2025年8月1-2日在 苏州 国际博览中心 举办（同期举办 第七届CMC-China博览会 ）！ 扫码！锁定免费参会名额！ 话题将覆盖： 农业、食品与能源， 医美、医药、大健康 ， 合成生物技术、中试放大与商业化， 以 及 项目路演 等多个方面，诚邀莅临，共襄盛举！ 往期精彩： 圆满落幕！下一站去哪？2023中国（苏州）合成生物学创新峰会成功举办 大会主办丨 Synbio深波 会议时间 | 2025年8月1-2日 会议地点 | 中国·苏州·国际博览中心B馆 扫码！锁定免费参会名额！ 往期嘉宾 阵容 （按首字母排序，排名不分先后， 嘉宾单位或头衔为参加往期活动时信息，或有改变 ） 2023中国(苏州)合成生物学产业技术峰会圆满落幕 合成生物，聚势苏州：2024中国合成生物学"科学家 ...

作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金各 方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投资家， 在产业发展中发挥着重要作用。 融行业智慧、共襄盛举 聚产业力量、擘画未来 第三届SynBio Suzhou中国合成生物学"科学家+企业家+投资家"大会 将于2025年8月1-2日在 苏州 国际博览中心 举办（同期举办 第七届CMC-China博览会 ）！ 扫码！锁定免费参会名额！ 话题将覆盖： 农业、食品与能源， 医美、医药、大健康 ， 合成生物技术、中试放大与商业化， 以 及 项目路演 等多个方面，诚邀莅临，共襄盛举！ 往期精彩： 圆满落幕！下一站去哪？2023中国（苏州）合成生物学创新峰会成功举办 大会主办丨 Synbio深波 会议时间 | 2025年8月1-2日 会议地点 | 中国·苏州·国际博览中心B馆 扫码！锁定免费参会名额！ 往期嘉宾 阵容 （按首字母排序，排名不分先后， 嘉宾单位或头衔为参加往期活动时信息，或有改变 ） 2023中国(苏州)合成生物学产业技术峰会圆满落幕 合成生物，聚势苏州：2024中国合成生物学"科学家 ...

近日，上交所举办央国企科创板上市公司高质量发展培训。 同时，上交所还召开了央企集团与央企 科创板上市公司座谈会，围绕央企积极布局科创板、推进新质生产力领域产业整合、加强市值管理 等方面开展深入交流，推动央企聚焦科技创新、加快产业转型，利用科创板平台的独特优势实现高 质量发展。 上交所有关负责人表示，将切实服务好国有企业深化改革提升行动，希望各央国企在产业并购整 合、培育壮大新质生产力、提高上市公司质量和投资价值等方面发挥引领示范作用，加快科技创新 和产业创新，更好支持实体经济和资本市场高质量发展。 产业并购： 央国企加快培育壮大新质生产力 作为国民经济的"压舱石"，央国企肩负保障社会民生、维护国家安全等重要使命，在资本市场上也 积极发挥带头作用。2024年，近40家央国企科创板公司披露"提质增效重回报"年度行动方案。 2025年3月，中科星图、江航装备、天玛智控等公司先后披露2025年相关行动方案，连续两年参与 专项行动。 在投资者回报方面，央企为市场树立了良好标杆。有央企代表介绍："公司自上市以来持续分红， 多年现金分红比例均超过20%，近两年公司还回购近亿元股票并实施注销，切实提升了投资者的获 得感。" ...